NL-OMON29873尚未招募不适用
Anticoagulation with nadroparin in continuous venovenous hemofiltration (CVVH): extracorporeal clearance and systemic effects of nadroparin - clearance and systemic effects of nadroparin in CVVH
Onze Lieve Vrouwe Gasthuis0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •non-surgical patients in the ICU with indication of CVVH for acute renal failure
排除标准
- •severe liver failure
- •active bleeding and need for transfusion
研究者
相似试验
已完成
4 期
Nadroparin Anticoagulation for Continuous Venovenous HemofiltrationKidneyAcute Renal FailureMultiple Organ FailureNCT00965328Onze Lieve Vrouwe Gasthuis14
已完成
不适用
Pharmacokinetics of nAdroparin in venous thromboembolism Prophylaxis in critically ill pAtients - an observational pilot study10064477Venous thromboembolismdeep venous thrombosisNL-OMON38854Meander Medisch Centrum30
已完成
不适用
iver Citrate Anticoagulation Threshold studyISRCTN92716512Fresenius Medical Care (Germany)120
已完成
4 期
Efficacy and Safety of Anticoagulant Therapy in Portal Vein ThrombosisLiver CirrhosisPortal Vein ThrombosisNCT04173429Qilu Hospital of Shandong University64
尚未招募
2 期
Danaparoid dosing during continuous venovenous hemofiltration - a randomized controlled pilot study investigating two danaparoid dosing schemes with a standard heparin dosing schemeacute kindey failureAcute renal failure10038430NL-OMON30497Academisch Medisch Centrum18